SCHEDULE 13G/A: Avidity Partners Discloses 9.9% Stake in Immunic, Inc. Common Stock

Avidity Partners Management LP and related entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.9% of Immunic, Inc.'s common stock as of December 31, 2024.

Summary

• Avidity Partners Management LP, along with its general partner Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, and Avidity Capital Partners (GP) LLC, collectively reported beneficial ownership of 9,022,363 shares of Immunic, Inc. common stock.
• This represents 9.9% of Immunic, Inc.'s outstanding common stock.
• Avidity Private Master Fund I LP, a related entity, separately reported beneficial ownership of 5,636,268 shares, representing 6.2% of the class.
• Michael Gregory, as Managing Member for several Avidity entities, also reported shared beneficial ownership of 9,022,363 shares, or 9.9%.
• All reported shares are held with shared voting and shared dispositive power by the respective entities.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of Immunic, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake (9.9%) by Avidity Partners in Immunic, Inc. is generally a positive signal, indicating investor confidence. The explicit statement that the stake is not for control purposes suggests a passive, long-term investment view, which can be reassuring to other shareholders.

Positives

• Significant institutional investment by Avidity Partners, indicating confidence in Immunic, Inc.
• The filing explicitly states that the shares are not held for the purpose of changing or influencing control, suggesting a passive investment stance.

Future Outlook

NA

Management Comments

• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

This filing reflects a standard disclosure of significant institutional ownership in a publicly traded biotechnology or pharmaceutical company, common for investment firms taking passive stakes in promising firms within the sector.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a vote of confidence, potentially stabilizing or positively influencing share price.

Key Dates

Keywords

Immunic Inc, IMMUN, Avidity Partners Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Equity Stake, Investment Management